MedTrace Logo

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

NCT00657891 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2013-10-01

No results posted yet for this study

Summary

We are studying Xolair (omalizumab) to see it's effect on allergic blood cells. The blood tests will be done in a test tube to see if they react differently before and after treatment. The blood cells will be mixed with to whatever the person is allergic.

Conditions

Interventions

DRUG

Omalizumab

0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously

DRUG

Placebo

Placebo Injection

Sponsors & Collaborators

Principal Investigators

  • Robert G Townley, MD · Creighton University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00657891 on ClinicalTrials.gov